The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: Primary and secondary prophylaxis for opportunistic infection if stable and initiated at least 3 months prior to study drug administration. Patients must have: * HIV-positive status. * One HIV RNA count \> 10,000 copies/ml within 30 days prior to entry, with a second count at least 3-fold above or below the first value. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Active medical problems including chronic diarrhea and active opportunistic infections such as cryptococcosis, Pneumocystis carinii, histoplasmosis, etc.. * Malignancy for which systemic therapy or radiation therapy is expected to be required during the study. * Any other disease or condition that would place a patient at undue risk or confound the results of the study. Concurrent Medication: Excluded: Systemic therapy for malignancy. Prior Medication: Excluded: * Zidovudine or any other nucleoside reverse transcriptase inhibitor. * Immunomodulators within one month prior to study drug administration. * Investigational drugs within 30 days prior to study drug administration. * Systemic cytotoxic chemotherapy within 3 months prior to study drug administration. Prior Treatment: Excluded: * Extended-field radiation therapy within 3 months prior to study drug administration. * Blood transfusion within 2 weeks prior to study drug administration.